Skip to main content
Erschienen in: Der Gynäkologe 5/2018

23.03.2018 | Kontrazeption | CME

Hormonelle Kontrazeption in Risiko- und Spezialsituationen

verfasst von: PD Dr. S. Segerer

Erschienen in: Die Gynäkologie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Schwerwiegende Komplikationen unter hormoneller Kontrazeption, z. B. venöse Thrombembolien oder ein Myokardinfarkt, betreffen überwiegend Frauen mit Risikofaktoren oder genetischer Prädisposition. Wichtig bei der Auswahl eines geeigneten Kontrazeptivums für Risikopatientinnen sind daher eine gezielte Eigen- und Familienanamnese bei Erstverordnung sowie eine allgemeine und gynäkologische Untersuchung, um mögliche Fallstricke vorab zu identifizieren. Wichtige kardiovaskuläre Risikofaktoren sind arterieller Hypertonus, Adipositas, Dyslipidämien, Rauchen und Diabetes mellitus. Bei Thrombophilien und im Falle von Systemerkrankungen wie Lupus erythematodes sollte ebenfalls ein erhöhtes Thromboserisiko berücksichtigt werden. Hilfreich bei der Entscheidung sind in der Praxis die Empfehlungen der World Health Organization, die auch die Kontrazeption in Sondersituationen abdecken. In einigen Fällen sind jedoch Einzelfallentscheidungen notwendig, ggf. auch in einem interdisziplinären Rahmen.
Literatur
2.
Zurück zum Zitat Dinger JC, Heinemann LA, Kuhl-Habich D (2007) The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75(5):344–354CrossRefPubMed Dinger JC, Heinemann LA, Kuhl-Habich D (2007) The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75(5):344–354CrossRefPubMed
3.
Zurück zum Zitat Dinger J, Mohner S, Heinemann K (2016) Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception 93(5):378–385CrossRefPubMed Dinger J, Mohner S, Heinemann K (2016) Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception 93(5):378–385CrossRefPubMed
4.
Zurück zum Zitat Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E (2012) Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344:e2990CrossRefPubMedPubMedCentral Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E (2012) Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344:e2990CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133(1):32–37CrossRefPubMed Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133(1):32–37CrossRefPubMed
6.
Zurück zum Zitat Gaussem P, Alhenc-Gelas M, Thomas JL, Bachelot-Loza C, Remones V, Ali FD et al (2011) Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 105(3):560–567CrossRefPubMed Gaussem P, Alhenc-Gelas M, Thomas JL, Bachelot-Loza C, Remones V, Ali FD et al (2011) Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 105(3):560–567CrossRefPubMed
7.
Zurück zum Zitat Dinger J, Do Minh T, Heinemann K (2016) Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 94(4):328–339CrossRefPubMed Dinger J, Do Minh T, Heinemann K (2016) Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 94(4):328–339CrossRefPubMed
8.
Zurück zum Zitat Han L, Jensen JT (2015) Does the progestogen used in combined hormonal contraception affect venous thrombosis risk? Obstet Gynecol Clin North Am 42(4):683–698CrossRefPubMed Han L, Jensen JT (2015) Does the progestogen used in combined hormonal contraception affect venous thrombosis risk? Obstet Gynecol Clin North Am 42(4):683–698CrossRefPubMed
9.
Zurück zum Zitat Blanco-Molina MA, Lozano M, Cano A, Cristobal I, Pallardo LP, Lete I (2012) Progestin-only contraception and venous thromboembolism. Thromb Res 129(5):e257–62 Blanco-Molina MA, Lozano M, Cano A, Cristobal I, Pallardo LP, Lete I (2012) Progestin-only contraception and venous thromboembolism. Thromb Res 129(5):e257–62
10.
Zurück zum Zitat Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME (2018) A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME (2018) A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet
11.
Zurück zum Zitat Practice Committee of the American Society for Reproductive Medicine (2017) Electronic address Aao, Practice Committee of the American Society for Reproductive M. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 107(1):43–51 Practice Committee of the American Society for Reproductive Medicine (2017) Electronic address Aao, Practice Committee of the American Society for Reproductive M. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 107(1):43–51
12.
Zurück zum Zitat Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344(8935):1453–1457CrossRefPubMed Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344(8935):1453–1457CrossRefPubMed
13.
Zurück zum Zitat Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B et al (2016) Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 127(11):1417–1425CrossRefPubMedPubMedCentral Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B et al (2016) Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 127(11):1417–1425CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Medical Eligibility Criteria for Contraceptive Use, 2015. 5th edition. Geneva: World Health Organization Medical Eligibility Criteria for Contraceptive Use, 2015. 5th edition. Geneva: World Health Organization
15.
Zurück zum Zitat van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR (2010) The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 30(11):2297–2300CrossRefPubMed van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR (2010) The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 30(11):2297–2300CrossRefPubMed
16.
Zurück zum Zitat Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366(24):2257–2266CrossRefPubMed Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366(24):2257–2266CrossRefPubMed
17.
Zurück zum Zitat Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M (2013) Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab 27(1):35–45CrossRefPubMed Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M (2013) Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab 27(1):35–45CrossRefPubMed
18.
Zurück zum Zitat Mant J, Painter R, Vessey M (1998) Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol 105(8):890–896CrossRefPubMed Mant J, Painter R, Vessey M (1998) Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol 105(8):890–896CrossRefPubMed
19.
Zurück zum Zitat D’Avanzo B, La Vecchia C, Negri E, Parazzini F, Franceschi S (1994) Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health 48(3):324–325CrossRefPubMedPubMedCentral D’Avanzo B, La Vecchia C, Negri E, Parazzini F, Franceschi S (1994) Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health 48(3):324–325CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Lidegaard O (1995) Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 102(2):153–159CrossRefPubMed Lidegaard O (1995) Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 102(2):153–159CrossRefPubMed
21.
Zurück zum Zitat Dilshad H, Yousuf RI, Shoaib MH, Jamil S, Khatoon H (2016) Cardiovascular disease risk associated with the long-term use of depot medroxyprogesterone acetate. Am J Med Sci 352:487–492PubMed Dilshad H, Yousuf RI, Shoaib MH, Jamil S, Khatoon H (2016) Cardiovascular disease risk associated with the long-term use of depot medroxyprogesterone acetate. Am J Med Sci 352:487–492PubMed
22.
Zurück zum Zitat Mensink GB, Schienkiewitz A, Haftenberger M, Lampert T, Ziese T, Scheidt-Nave C (2013) Overweight and obesity in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(5–6):786–794CrossRefPubMed Mensink GB, Schienkiewitz A, Haftenberger M, Lampert T, Ziese T, Scheidt-Nave C (2013) Overweight and obesity in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(5–6):786–794CrossRefPubMed
23.
Zurück zum Zitat Horton LG, Simmons KB, Curtis KM (2016) Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 94(6):590–604CrossRefPubMed Horton LG, Simmons KB, Curtis KM (2016) Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 94(6):590–604CrossRefPubMed
24.
Zurück zum Zitat Brunner Huber LR, Hogue CJ, Stein AD, Drews C, Zieman M (2006) Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Ann Epidemiol 16(8):637–643CrossRefPubMed Brunner Huber LR, Hogue CJ, Stein AD, Drews C, Zieman M (2006) Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Ann Epidemiol 16(8):637–643CrossRefPubMed
25.
Zurück zum Zitat Brunner LR, Hogue CJ (2005) The role of body weight in oral contraceptive failure: results from the 1995 national survey of family growth. Ann Epidemiol 15(7):492–499CrossRefPubMed Brunner LR, Hogue CJ (2005) The role of body weight in oral contraceptive failure: results from the 1995 national survey of family growth. Ann Epidemiol 15(7):492–499CrossRefPubMed
26.
Zurück zum Zitat Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR (2005) Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 105(1):46–52CrossRefPubMed Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR (2005) Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 105(1):46–52CrossRefPubMed
27.
Zurück zum Zitat Holt VL, Cushing-Haugen KL, Daling JR (2002) Body weight and risk of oral contraceptive failure. Obstet Gynecol 99(5 Pt 1):820–827PubMed Holt VL, Cushing-Haugen KL, Daling JR (2002) Body weight and risk of oral contraceptive failure. Obstet Gynecol 99(5 Pt 1):820–827PubMed
28.
Zurück zum Zitat Vessey M (2001) Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann Reprod Health Care 27(2):90–91CrossRefPubMed Vessey M (2001) Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann Reprod Health Care 27(2):90–91CrossRefPubMed
29.
Zurück zum Zitat Lopez LM, Grimes DA, Chen M, Otterness C, Westhoff C, Edelman A et al (2013) Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2013(4):CD008452 Lopez LM, Grimes DA, Chen M, Otterness C, Westhoff C, Edelman A et al (2013) Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2013(4):CD008452
30.
Zurück zum Zitat McNicholas C, Zhao Q, Secura G, Allsworth JE, Madden T, Peipert JF (2013) Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 121(3):585–592CrossRefPubMedPubMedCentral McNicholas C, Zhao Q, Secura G, Allsworth JE, Madden T, Peipert JF (2013) Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 121(3):585–592CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Black A, Guilbert E, Co A, Costescu D, Dunn S, Fisher W, et al (2015) Canadian Contraception Consensus (Part 2 of 4). J Obstet Gynaecol Can 37(11):1033–1039CrossRefPubMed Black A, Guilbert E, Co A, Costescu D, Dunn S, Fisher W, et al (2015) Canadian Contraception Consensus (Part 2 of 4). J Obstet Gynaecol Can 37(11):1033–1039CrossRefPubMed
33.
Zurück zum Zitat Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87(1):4–14CrossRefPubMed Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87(1):4–14CrossRefPubMed
34.
Zurück zum Zitat Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D et al (1997) A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20(3):330–335CrossRefPubMed Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D et al (1997) A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20(3):330–335CrossRefPubMed
35.
Zurück zum Zitat Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B et al (1992) Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35(10):967–972CrossRefPubMed Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B et al (1992) Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35(10):967–972CrossRefPubMed
36.
Zurück zum Zitat Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373(9677):1773–1779CrossRefPubMed Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373(9677):1773–1779CrossRefPubMed
37.
Zurück zum Zitat Beydoun HA, Beydoun MA, Tamim H (2009) How does gestational diabetes affect postpartum contraception in nondiabetic primiparous women? Contraception 79(4):290–296CrossRefPubMed Beydoun HA, Beydoun MA, Tamim H (2009) How does gestational diabetes affect postpartum contraception in nondiabetic primiparous women? Contraception 79(4):290–296CrossRefPubMed
38.
Zurück zum Zitat Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B et al (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323(20):1375–1381CrossRefPubMed Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B et al (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323(20):1375–1381CrossRefPubMed
39.
Zurück zum Zitat Lopez LM, Grimes DA, Schulz KF (2014) Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014(4):CD006133 Lopez LM, Grimes DA, Schulz KF (2014) Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014(4):CD006133
40.
Zurück zum Zitat Troisi RJ, Cowie CC, Harris MI (2000) Oral contraceptive use and glucose metabolism in a national sample of women in the united states. Am J Obstet Gynecol 183(2):389–395CrossRefPubMed Troisi RJ, Cowie CC, Harris MI (2000) Oral contraceptive use and glucose metabolism in a national sample of women in the united states. Am J Obstet Gynecol 183(2):389–395CrossRefPubMed
41.
Zurück zum Zitat Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE (1994) Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 271(14):1099–1102CrossRefPubMed Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE (1994) Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 271(14):1099–1102CrossRefPubMed
42.
Zurück zum Zitat Klein BE, Moss SE, Klein R (1990) Oral contraceptives in women with diabetes. Diabetes Care 13(8):895–898CrossRefPubMed Klein BE, Moss SE, Klein R (1990) Oral contraceptives in women with diabetes. Diabetes Care 13(8):895–898CrossRefPubMed
43.
Zurück zum Zitat Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM et al (2005) Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 28(8):1988–1994CrossRefPubMed Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM et al (2005) Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 28(8):1988–1994CrossRefPubMed
44.
Zurück zum Zitat Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P et al (1982) Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25(6):618–623CrossRefPubMed Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P et al (1982) Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25(6):618–623CrossRefPubMed
45.
Zurück zum Zitat Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353(24):2550–2558CrossRefPubMed Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353(24):2550–2558CrossRefPubMed
46.
Zurück zum Zitat Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH et al (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353(24):2539–2549CrossRefPubMed Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH et al (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353(24):2539–2549CrossRefPubMed
47.
Zurück zum Zitat Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485CrossRefPubMedPubMedCentral Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Johnston RD, Logan RF (2008) What is the peak age for onset of IBD? Inflamm Bowel Dis 14(Suppl 2):S4–S5CrossRefPubMed Johnston RD, Logan RF (2008) What is the peak age for onset of IBD? Inflamm Bowel Dis 14(Suppl 2):S4–S5CrossRefPubMed
49.
Zurück zum Zitat Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF (2014) Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 8(6):469–479CrossRefPubMed Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF (2014) Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 8(6):469–479CrossRefPubMed
50.
Zurück zum Zitat Grainge MJ, West J, Card TR (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375(9715):657–663CrossRefPubMed Grainge MJ, West J, Card TR (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375(9715):657–663CrossRefPubMed
51.
Zurück zum Zitat Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK (2016) U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016 Jul 29;65(3):1–103. https://doi.org/10.15585/mmwr.rr6503a1 Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK (2016) U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016 Jul 29;65(3):1–103. https://​doi.​org/​10.​15585/​mmwr.​rr6503a1
52.
Zurück zum Zitat Zapata LB, Paulen ME, Cansino C, Marchbanks PA, Curtis KM (2010) Contraceptive use among women with inflammatory bowel disease: A systematic review. Contraception 82(1):72–85CrossRefPubMed Zapata LB, Paulen ME, Cansino C, Marchbanks PA, Curtis KM (2010) Contraceptive use among women with inflammatory bowel disease: A systematic review. Contraception 82(1):72–85CrossRefPubMed
53.
Zurück zum Zitat Klaeboe L, Lonn S, Scheie D, Auvinen A, Christensen HC, Feychting M et al (2005) Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. Int J Cancer 117(6):996–1001CrossRefPubMed Klaeboe L, Lonn S, Scheie D, Auvinen A, Christensen HC, Feychting M et al (2005) Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. Int J Cancer 117(6):996–1001CrossRefPubMed
54.
Zurück zum Zitat Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H (2006) Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80(1):1–7CrossRefPubMed Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H (2006) Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80(1):1–7CrossRefPubMed
55.
Zurück zum Zitat Lusis EA, Scheithauer BW, Yachnis AT, Fischer BR, Chicoine MR, Paulus W et al (2012) Meningiomas in pregnancy: a clinicopathologic study of 17 cases. Neurosurgery 71(5):951–961CrossRefPubMed Lusis EA, Scheithauer BW, Yachnis AT, Fischer BR, Chicoine MR, Paulus W et al (2012) Meningiomas in pregnancy: a clinicopathologic study of 17 cases. Neurosurgery 71(5):951–961CrossRefPubMed
56.
Zurück zum Zitat Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, et al (2018) Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neurooncol 136(2):327–333CrossRefPubMed Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, et al (2018) Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neurooncol 136(2):327–333CrossRefPubMed
57.
Zurück zum Zitat Niedziela N, Adamczyk-Sowa M, Pierzchala K (2014) Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review. Int J Neurosci 124(5):322–330CrossRefPubMed Niedziela N, Adamczyk-Sowa M, Pierzchala K (2014) Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review. Int J Neurosci 124(5):322–330CrossRefPubMed
58.
Zurück zum Zitat Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C et al (2009) The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART’MUS) trial: rationale, objectives and state of advancement. J Neurol Sci 286(1–2):114–118CrossRefPubMed Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C et al (2009) The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART’MUS) trial: rationale, objectives and state of advancement. J Neurol Sci 286(1–2):114–118CrossRefPubMed
59.
Zurück zum Zitat Vessey MP, Lawless M (1984) The Oxford-Family Planning Association contraceptive study. Clin Obstet Gynaecol 11(3):743–757PubMed Vessey MP, Lawless M (1984) The Oxford-Family Planning Association contraceptive study. Clin Obstet Gynaecol 11(3):743–757PubMed
60.
Zurück zum Zitat Thorogood M, Hannaford PC (1998) The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 105(12):1296–1299CrossRefPubMed Thorogood M, Hannaford PC (1998) The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 105(12):1296–1299CrossRefPubMed
61.
Zurück zum Zitat Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A (2000) Oral contraceptives and the incidence of multiple sclerosis. Neurology 55(6):848–854CrossRefPubMed Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A (2000) Oral contraceptives and the incidence of multiple sclerosis. Neurology 55(6):848–854CrossRefPubMed
62.
Zurück zum Zitat Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62(9):1362–1365CrossRefPubMed Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62(9):1362–1365CrossRefPubMed
64.
Zurück zum Zitat Ball SJ, Pereira G, Jacoby P, de Klerk N, Stanley FJ (2014) Re-evaluation of link between interpregnancy interval and adverse birth outcomes: retrospective cohort study matching two intervals per mother. BMJ 349:g4333CrossRefPubMedPubMedCentral Ball SJ, Pereira G, Jacoby P, de Klerk N, Stanley FJ (2014) Re-evaluation of link between interpregnancy interval and adverse birth outcomes: retrospective cohort study matching two intervals per mother. BMJ 349:g4333CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143(10):697–706CrossRefPubMed Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143(10):697–706CrossRefPubMed
66.
Zurück zum Zitat Jackson E, Curtis KM, Gaffield ME (2011) Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 117(3):691–703CrossRefPubMed Jackson E, Curtis KM, Gaffield ME (2011) Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 117(3):691–703CrossRefPubMed
67.
Zurück zum Zitat Kapp N, Curtis KM (2010) Combined oral contraceptive use among breastfeeding women: a systematic review. Contraception 82(1):10–16CrossRefPubMed Kapp N, Curtis KM (2010) Combined oral contraceptive use among breastfeeding women: a systematic review. Contraception 82(1):10–16CrossRefPubMed
68.
Zurück zum Zitat Kapp N, Curtis K, Nanda K (2010) Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception 82(1):17–37CrossRefPubMed Kapp N, Curtis K, Nanda K (2010) Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception 82(1):17–37CrossRefPubMed
69.
Zurück zum Zitat Lopez LM, Grey TW, Stuebe AM, Chen M, Truitt ST, Gallo MF (2015) Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2015(3):CD003988 Lopez LM, Grey TW, Stuebe AM, Chen M, Truitt ST, Gallo MF (2015) Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2015(3):CD003988
70.
Zurück zum Zitat Tepper NK, Phillips SJ, Kapp N, Gaffield ME, Curtis KM (2016) Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. Contraception 94(3):262–274CrossRefPubMed Tepper NK, Phillips SJ, Kapp N, Gaffield ME, Curtis KM (2016) Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. Contraception 94(3):262–274CrossRefPubMed
71.
Zurück zum Zitat Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312(7023):83–88CrossRefPubMedPubMedCentral Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312(7023):83–88CrossRefPubMedPubMedCentral
72.
Zurück zum Zitat Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346(8990):1589–1593CrossRefPubMed Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346(8990):1589–1593CrossRefPubMed
73.
Zurück zum Zitat de Bastos M et al (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014(3):CD010813 de Bastos M et al (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014(3):CD010813
74.
Zurück zum Zitat Grimes DA, Stuart GS, Levi EE (2012) Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol 120(4):889–895CrossRefPubMed Grimes DA, Stuart GS, Levi EE (2012) Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol 120(4):889–895CrossRefPubMed
76.
Zurück zum Zitat Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F (2006) Association of meningioma with reproductive factors. Int J Cancer 119(5):1152–1157CrossRefPubMed Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F (2006) Association of meningioma with reproductive factors. Int J Cancer 119(5):1152–1157CrossRefPubMed
77.
Zurück zum Zitat Custer B, Longstreth WT Jr., Phillips LE, Koepsell TD, Van Belle G (2006) Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6:152CrossRefPubMedPubMedCentral Custer B, Longstreth WT Jr., Phillips LE, Koepsell TD, Van Belle G (2006) Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6:152CrossRefPubMedPubMedCentral
78.
Zurück zum Zitat Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M et al (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164(7):629–636CrossRefPubMed Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M et al (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164(7):629–636CrossRefPubMed
79.
Zurück zum Zitat Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A (2010) Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control 21(12):2149–2156CrossRefPubMed Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A (2010) Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control 21(12):2149–2156CrossRefPubMed
Metadaten
Titel
Hormonelle Kontrazeption in Risiko- und Spezialsituationen
verfasst von
PD Dr. S. Segerer
Publikationsdatum
23.03.2018
Verlag
Springer Medizin
Erschienen in
Die Gynäkologie / Ausgabe 5/2018
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-018-4229-1

Weitere Artikel der Ausgabe 5/2018

Der Gynäkologe 5/2018 Zur Ausgabe

Einführung zum Thema

Brustkrebsfrüherkennung

Update Gynäkologie

Update Gynäkologie

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.